Key Releases are ad hoc announcements pursuant to SIX Swiss Exchange Article 53 Listing Rules.
Header
News archive
News Archive Navigation
icon
News Archive Navigation Language
Language Preferences
Showing 1800 results
June 2016
-
Media ReleaseNovartis adds bispecific antibodies to its growing immuno-oncology portfolio through collaboration and licensing agreement with XencorAgreement is the latest in a series of acquisitions and strategic collaborations that have bolstered Novartis' deep and diverse immuno-oncology pipeline Collaboration will co-develop Xencor's…
-
Tuning drugs to succeed on the cell’s surface
Researchers improve our understanding about how compounds bind to proteins in the cell membrane—and the membrane itself.
-
Media ReleaseTimely use of Novartis' Entresto could prevent or postpone over 28,000 US deaths per year among HFrEF patients, according to an expert analysis in JAMA CardiologyFindings are first to quantify magnitude of potential survival benefits if Entresto were prescribed to all eligible US HFrEF patients (as defined by authors) [1] Cardiology experts…
-
In The NewsExpanding access to healthcare: What will it really take?Head of global nonprofit PATH explores how “social innovation” such as the Novartis Access program is helping expand access to healthcare in some of the world’s poorest countries.
-
In The NewsMalaria's deadly comebackIn an editorial for Project Syndicate, Nick White, Professor of Tropical Medicine at the Mahidol Oxford Tropical Medicine Research Unit in Bangkok, and Thierry Diagana, Head of the Novartis Institute…
-
Tackling the common denominator in liver disease
Researchers focus on reversing the scarring that’s common to liver diseases.
-
Migraine: One of the world’s most common diseases
Did you know migraine is the most common of all neurological disorders? Learn more surprising facts.
-
Media ReleaseNovartis expands partnership with Medicines for Malaria Venture to develop next-generation antimalarial treatmentNovartis will lead the development of antimalarial compound KAF156 with scientific and financial support from Medicines for Malaria Venture in collaboration with the Bill & Melinda Gates…
-
Media ReleaseNovartis erweitert Partnerschaft mit Medicines for Malaria Venture zur Entwicklung von Malariamedikamenten der nächsten GenerationNovartis wird die Entwicklung des Malariapräparats KAF156 mit wissenschaftlicher und finanzieller Unterstützung von Medicines for Malaria Venture in Zusammenarbeit mit der Bill & Melinda Gates…
-
Media ReleaseNovartis étend son partenariat avec Medicines for Malaria Venture pour développer la prochaine génération de traitement antipaludéenNovartis dirigera le développement de la molécule antipaludique KAF156 avec le soutien scientifique et financier de Medicines for Malaria Venture et en collaboration avec la Fondation Bill &…
-
Media ReleaseNovartis highlights long-term safety data of Revolade® in adults with chronic immune thrombocytopenia, a rare blood disorderEXTEND study provides long-term safety data for Revolade that are consistent with the findings from the pivotal Phase III RAISE study[1,2] Immune thrombocytopenia (ITP) is a rare and potentially…
-
Media ReleaseNovartis presents data showing Jakavi® is superior to best available therapy in patients with less advanced polycythemia vera (PV)Three times as many patients with inadequately controlled PV without enlarged spleen had hematocrit control without phlebotomy on Jakavi® (ruxolitinib) vs BAT[1] RESPONSE-2 complements data…
Pagination
- ‹ Previous page
- 1
- …
- 122
- 123
- 124
- 125
- 126
- 127
- 128
- …
- 150
- › Next page